Vimarsana
Biggest News Aggregation in the World

Page 14 - Nasdaq Edit News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq Edit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Edit Today - Breaking & Trending Today

Bruce Eaton Sells 1,258 Shares of Editas Medicine, Inc. (NASDAQ:EDIT) Stock - Vimarsana News

Bruce Eaton Sells 1,258 Shares of Editas Medicine, Inc. (NASDAQ:EDIT) Stock

Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) EVP Bruce Eaton sold 1,258 shares of the company’s stock in a transaction dated Friday, April 1st. The shares were sold at an average price of $19.64, for a total transaction of $24,707.12. The transaction was disclosed in a legal filing with the SEC, which is accessible through […]

Editas Medicine, Inc. (NASDAQ:EDIT) Receives Average Rating of "Hold" from Brokerages - Vimarsana News

Editas Medicine, Inc. (NASDAQ:EDIT) Receives Average Rating of "Hold" from Brokerages

Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) has earned a consensus recommendation of “Hold” from the thirteen research firms that are covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the company. The average 12-month […]

Editas Medicine, Inc. (NASDAQ:EDIT) Shares Purchased by Cetera Advisor Networks LLC - Vimarsana News

Editas Medicine, Inc. (NASDAQ:EDIT) Shares Purchased by Cetera Advisor Networks LLC

Cetera Advisor Networks LLC boosted its position in Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) by 8.4% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,667 shares of the company’s stock after purchasing an additional 671 shares during the period. Cetera Advisor Networks […]

Editas Medicine Announces Favorable Decision from U.S. - Vimarsana News

Editas Medicine Announces Favorable Decision from U.S.

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, announced today the U.S....

Editas Medicine Reports Preclinical Data Demonstrating - Vimarsana News

Editas Medicine Reports Preclinical Data Demonstrating

Preclinical data demonstrating Editas-engineered AsCas12a multiplexed editing of iPSCs enhances iNK tumor killing ability, supporting promise as a...